Winston Pharmaceuticals, Inc. announced that the National Institutes of Health has awarded Winston a grant under the Small Business Innovation Research program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia of the trigeminal nerve (TN). The phase I award in the amount of approximately $375,000 will be administered by the National Institute of Neurological Disorders and Stroke.